StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Valeant Pharma's (VRX) Ad Hoc Committee Completes Review; No Additional Items for Restatement Identified
April 5, 2016 8:49 AM
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that the ad hoc committee of the board of directors (the "Ad Hoc ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Hot Corp. News
Litigation
Short Sales
Trader Talk
Next Articles
Conclusion of Valeant's (VRX) Ad Hoc Committee Review is Positive Development - Moody's
April 5, 2016 2:18 PM
Valeant (VRX) Could Be on the Verge of a Significant Inflection Point - BMO Capital
April 5, 2016 10:09 AM
Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters
April 5, 2016 8:48 AM
Valeant Pharma (VRX) said to terminate Addyi sales force in reorganization - Bloomberg
April 4, 2016 5:07 PM
Some Valeant Pharma (VRX) Creditors Said Against Proposal to Relax Loan Pact
April 4, 2016 3:53 PM
U.S. regulator sues ValueAct over Halliburton-Baker Hughes disclosures
April 4, 2016 1:08 PM
Valeant Pharma (VRX), Progenics (PGNX) PDUFA for Oral RELISTOR Extended by 3 Months
April 4, 2016 7:03 AM
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR
April 4, 2016 7:00 AM
Ackman's fund falls 7 percent in March, hurt by Valeant
April 1, 2016 6:43 PM
